TrialLineage Lineage
Phase 3 · ActiveTargeting fibrosis signaling in idiopathic pulmonary fibrosis
This lineage starts with a Phase 3 trial of an oral drug targeting the LPA1 receptor in IPF, then traces backward through the chain of science that made it possible: fibrosis pathology, fibroblast biology, lipid signaling, receptor pharmacology, and antifibrotic drug development.
In plain language
The drug, the disease, and the chain of science behind both
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease in which scar tissue gradually replaces normal lung tissue, making it harder and harder to breathe. Two existing drugs can slow it down. Neither stops it. Median survival is 3–5 years from diagnosis.
BMS-986278 is an investigational oral drug designed to block the LPA1 receptor — a molecular switch that activates fibroblasts, the cells responsible for producing scar tissue. If blocking LPA1 reduces fibroblast activation, the progressive scarring that destroys lung function may slow.
But this trial did not appear from nowhere. It exists because of decades of work: pathologists who identified the disease pattern, cell biologists who understood fibroblasts, biochemists who discovered LPA as a signaling molecule, molecular biologists who cloned LPA receptors, and medicinal chemists who designed a drug to block one. This page traces that chain.
At a glance
- The drug: BMS-986278, an oral LPA1 receptor antagonist
- The disease: idiopathic pulmonary fibrosis — progressive, irreversible lung scarring with limited treatment options
- The target: LPA1, a receptor that drives fibroblast activation and collagen production in the lung
- The trial: NCT06003426, Phase 3, measuring whether LPA1 blockade slows the rate of lung function decline (FVC)
- Why it took decades: IPF was first treated as inflammation (wrong). LPA had to be recognized as a signaling molecule. LPA1 had to be cloned. Selective chemistry had to be designed. An endpoint had to be validated.
What had to happen first?
Six steps that made this trial possible
None of these steps alone produced a drug. Each one built on the last, and the full chain took decades to assemble.
1
Name the disease
Pathologists described a distinct pattern of progressive lung scarring and gave it a name: usual interstitial pneumonia / IPF.
2
Understand fibroblasts
Cell biologists identified fibroblasts as the primary effector cells of tissue scarring — not inflammation, not dead tissue.
3
Abandon the wrong hypothesis
Anti-inflammatory treatments failed. The field recognized IPF as aberrant wound healing, not chronic inflammation.
4
Discover LPA signaling
Biochemists found that lysophosphatidic acid is a potent bioactive lipid that drives fibroblast activation through specific receptors.
5
Design a selective drug
Medicinal chemists built an orally available small molecule that selectively blocks LPA1 without disrupting other LPA receptors.
6
Validate the endpoint
Pirfenidone and nintedanib trials established FVC decline rate as a regulatory-accepted measure of IPF progression.
Reverse-lineage map
How this trial traces back through science
Read from top to bottom to see the chain of scientific fields that built on each other. Side branches show where the path diverged, where earlier approaches failed, and where enabling work de-risked key steps.
Failed approach
Anti-inflammatory treatment
Corticosteroids and immunosuppressants were tried for decades. They failed — IPF is not primarily an inflammatory disease.
Enabling method
LPA1 knockout mice
Mice lacking LPA1 showed significantly reduced lung fibrosis after injury — confirming the receptor as a druggable target.
Enabling method
FVC as a regulatory endpoint
Pirfenidone and nintedanib trials validated FVC decline rate as an accepted primary endpoint for IPF drug approval.
Clinical trial
Phase 3: BMS-986278 in IPF
Phase 2 evidence
Tolerability and potential efficacy signal
Drug design
Oral selective LPA1 antagonist
Target validation
LPA1 linked to fibrosis in lung
Receptor biology
LPA receptors cloned and characterized
Lipid signaling
LPA identified as bioactive signaling molecule
Conceptual shift
IPF redefined as aberrant wound healing
Cell biology
Fibroblasts and extracellular matrix
Pathology
Lung fibrosis recognized as distinct disease
Branch point
Multiple antifibrotic pathways
TGF-beta, PDGF, Wnt, and other pathways also drive fibrosis. LPA1 is one of several active drug targets.
Enabling method
Pirfenidone and nintedanib (2014)
First-generation antifibrotics proved the concept and built the regulatory/clinical framework BMS-986278 now uses.
Open question
Single-pathway sufficiency
Is blocking LPA1 alone enough? Or does fibrosis require combination approaches targeting redundant pathways?
Failed approach
Anti-inflammatory treatment
Corticosteroids failed. IPF is not primarily inflammatory.
Enabling method
LPA1 knockout mice
Confirmed the receptor as a druggable target.
Enabling method
FVC as a regulatory endpoint
Pirfenidone/nintedanib trials validated the primary endpoint.
Branch point
Multiple antifibrotic pathways
LPA1 is one of several active drug targets.
Enabling method
Pirfenidone and nintedanib
First-generation antifibrotics built the framework.
Open question
Single-pathway sufficiency
Is blocking LPA1 alone enough?
Discovery timeline
Key moments in the path to this trial
Each step below made the next step possible. Without any one of them, this Phase 3 trial would not exist.
Lung fibrosis recognized as a distinct pathology
Pathologists described progressive lung scarring distinct from infection or cancer. By the 1960s, “usual interstitial pneumonia” (UIP) was identified as the histological pattern underlying what would become IPF.
Fibroblasts and extracellular matrix become central
Cell biologists identified fibroblasts as the primary effector cells of tissue scarring. The concept of extracellular matrix as an active, remodeled structure changed how scientists understood fibrosis — it could be studied as a problem of cell behavior.
Anti-inflammatory approaches fail
Patients received corticosteroids and immunosuppressants for decades. They were ineffective and sometimes harmful. This long failure eventually forced a conceptual shift — away from inflammation and toward aberrant wound healing.
IPF redefined as aberrant wound healing
Researchers recognized that IPF is not chronic inflammation but disordered tissue repair — repetitive microscopic lung injury activating fibroblasts through wound-healing pathways that never resolve. This redirected the field toward profibrotic signaling.
LPA identified as a bioactive signaling lipid
Biochemists discovered that lysophosphatidic acid is not merely a metabolic intermediate but a potent signaling molecule that activates cell proliferation, migration, and survival through specific G protein-coupled receptors.
LPA receptors cloned and characterized
Molecular biologists cloned LPA1, LPA2, and LPA3 and mapped their tissue distribution. LPA1 was found in fibroblasts and lung tissue. Each receptor had distinct effects, making selective targeting conceivable.
LPA and LPA1 linked to fibrosis in the lung
LPA levels were found elevated in IPF lungs. LPA1 signaling promoted fibroblast recruitment, proliferation, and collagen production. LPA1 knockout mice showed reduced fibrosis after lung injury. LPA1 became a druggable profibrotic target.
Small-molecule LPA1 antagonists designed
Medicinal chemists developed orally bioavailable molecules that selectively block LPA1. Drug design required balancing receptor selectivity, oral absorption, metabolic stability, and potency. BMS-986278 emerged from this work.
Pirfenidone and nintedanib establish the framework
These first-generation antifibrotics validated two things simultaneously: that antifibrotic drugs could slow IPF, and that FVC decline rate was an acceptable primary endpoint for regulatory approval. They built the trial framework BMS-986278 now uses.
Phase 2 clinical evidence
A Phase 2 trial of BMS-986278 provided initial evidence of tolerability and suggested a potential treatment effect on lung function decline. These results supported advancement to Phase 3.
Phase 3: testing whether LPA1 antagonism slows IPF
The Phase 3 trial (NCT06003426) evaluates whether BMS-986278 produces clinically meaningful reduction in FVC decline. Decades of accumulated knowledge — from fibrosis pathology to lipid signaling to receptor pharmacology to endpoint validation — converges into a controlled experiment.
Why this lineage matters
This lineage shows how pulmonary fibrosis can be approached not as scar tissue already formed, but as a disease process shaped by injury-repair signaling, fibroblast behavior, and molecular pathways that may be therapeutically targeted. It required a major conceptual shift: from treating IPF as inflammation (which failed) to understanding it as aberrant wound healing.
A wrong hypothesis had to fail first
Decades of anti-inflammatory treatment failed. That failure was not wasted — it forced the field to rethink the disease mechanism entirely. The current trial exists because the wrong answer was pursued long enough to be disproven.
The question this trial answers
Whether selective LPA1 receptor blockade translates into meaningful slowing of lung function decline. The scientific lineage is coherent; the clinical outcome is still unknown.
Deep-dive view
The longer scientific lineage
Each section below expands on one layer of the discovery chain.
1. Fibrosis had to become a cell-biology problem
Before IPF could be treated mechanistically, scientists had to understand that fibrosis is driven by specific cells (fibroblasts) producing specific molecules (extracellular matrix proteins). The concept of fibrosis as active cellular behavior — not just dead tissue — opened it to therapeutic targeting.
2. The inflammation hypothesis had to fail
For decades, the default explanation was that lung scarring resulted from chronic inflammation. Corticosteroids and immunosuppressants were the standard. They did not work. This long, costly failure eventually forced the field to ask different questions about what drives fibroblast activation in the absence of ongoing inflammation.
3. A lipid had to be recognized as a signal
LPA was long considered a metabolic intermediate. The discovery that it signals through specific cell-surface receptors to drive proliferation, migration, and survival reframed it as a potential disease mediator. Finding elevated LPA in fibrotic lungs then connected it to IPF specifically.
4. A receptor had to be cloned and validated
LPA signals through multiple receptors. Cloning LPA1 and showing that it specifically mediates profibrotic effects — and that LPA1 knockout mice are protected from lung fibrosis — provided the target validation needed to justify drug development.
5. Chemistry had to produce a selective oral drug
Knowing the target is not enough. Medicinal chemists had to design a molecule that selectively blocks LPA1 (not LPA2 or LPA3), is orally bioavailable, metabolically stable, and potent enough to produce a biological effect at tolerable doses.
6. The full chain converges in a Phase 3 trial
The Phase 3 trial tests whether selective LPA1 blockade slows the rate of lung function decline in IPF patients. Every upstream step — from disease recognition to the failure of inflammation, to LPA biology, to receptor pharmacology, to endpoint validation — had to succeed before this experiment could exist.
Known vs. unknown
What the evidence says and what remains open
Established
- IPF is a progressive fibrotic lung disease with limited treatment options
- LPA levels are elevated in fibrotic lungs
- LPA1 signaling promotes fibroblast activation and collagen production
- LPA1 knockout mice show reduced fibrosis after lung injury
- BMS-986278 is a selective oral LPA1 receptor antagonist
- Phase 2 data supported advancement to Phase 3
- FVC decline rate is an accepted primary endpoint
Not yet known
- Whether BMS-986278 produces clinically meaningful slowing of FVC decline
- Whether LPA1 antagonism alone is sufficient to alter IPF progression
- How much of IPF fibrotic drive is LPA1-dependent vs. redundant pathways
- Whether the drug provides benefit beyond existing antifibrotics
- Long-term safety and tolerability
- Whether combination with pirfenidone/nintedanib is more effective
Related concept pages
Connected scientific fields
Source
Trial record
ClinicalTrials.gov — NCT06003426: A Study of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis.
The scientific lineage on this page draws on published research in pulmonary medicine, fibrosis biology, lipid biochemistry, and receptor pharmacology.